Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin after brief psychological therapy for anxiety and depression
ACTRN12624000816550Phase 2Not yet recruiting
- Sponsor
- University of Otago
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in anxiety disorder and major depressive disorder (MDD), sponsored by University of Otago. Primary endpoints: Recruitment and retention rates at dosing and follow-up and Adherence to protocol. Planned start May 2025; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12624000816550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000816550.